Paris-based artificial intelligence firm Gleamer recently raised almost $8.8 million (USD) in funds, including contributions from 37 radiologists, the company said Thursday.
European investment firm XAnge led the way in this Series A round, with additional money from insurer MACSF and two others. Gleamer said the money will help boost the launch of its BoneView AI platform in the Middle East, Asia and Latin America.
Company officials are also targeting U.S. Food and Drug Administration clearance for the program, which detects traumatic injuries in radiographic images and sends them to physicians for final validation. A recent clinical study including 600 patients found that BoneView helped lower the rate of undetected injury by 30%.
The solution already received a CE mark of approval in Europe this past March and is now live in 50 French hospitals employing 800 radiologists, Gleamer reported Wednesday.